Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency.
Sci Rep
; 12(1): 8433, 2022 05 19.
Article
in En
| MEDLINE
| ID: mdl-35589938
ABSTRACT
CAP256V2LS, a broadly neutralizing monoclonal antibody (bNAb), is being pursued as a promising drug for HIV-1 prevention. The total level of tyrosine-O-sulfation, a post-translational modification, was known to play a key role for antibody biological activity. More importantly, here wedescribe for the first time the significance of the tyrosine-O-sulfation proteoforms. We developed a hydrophobic interaction chromatography (HIC) method to separate and quantify different sulfation proteoforms, which led to the direct functionality assessment of tyrosine-sulfated species. The fully sulfated (4-SO3) proteoform demonstrated the highest in vitro relative antigen binding potency and neutralization efficiency against a panel of HIV-1 viruses. Interestingly, highly variable levels of 4-SO3 were produced by different clonal CHO cell lines, which helped the bNAb process development towards production of a highly potent CAP256V2LS clinical product with high 4-SO3 proteoform. This study presents powerful insight for any biotherapeutic protein development where sulfation may play an important role in product efficacy.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
HIV-1
Limits:
Animals
Language:
En
Journal:
Sci Rep
Year:
2022
Document type:
Article
Affiliation country:
Estados Unidos